RankAlpha logo
Back to Rankings

NAMS

NewAmsterdamF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Composite grade F from latest DB weights. Momentum 7.0 / Value 41.2
Posture
Defensive
Lead driver
Value
What changed
2 setup hits (3d) with net bearish as of 2026-09-09.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
7
Value
41
Sentiment
N/A
Setup hits (3d)
2 · Net Bearish
AI TargetsBase - · Bull - · Bear -Analysis date unavailable; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesis
As of 2026-09-08

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bearish
Target $51.80
Why
Momentum7 · Δ7d -4.6
Value41 · Δ7d -0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Bearish). Prioritize risk control and patience.

Confirming evidence

  • 2 setup hits (3d) with net bearish as of 2026-09-09.
  • Value remains the lead driver in the composite, 7D delta -0.0.

Contradictions & invalidation

  • Mixed signals. Wait for cleaner trend confirmation.

Catalyst clock

No dated catalyst is available.

Lead driver: Value · See fundamentals
Momentum
7
25% active weight
Current posture
7d trendSoftening
Δ7d
-4.6
Δ21d
-2.0
Value
41
75% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 7.0 / Value 41.2

Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.22B
Beta
0.07
Shares Out
119.54M
P/E (TTM) · Derived
-15.6
P/S (TTM)
107.72
P/FCF (TTM) · Derived
-22.34
Rev YoY
-80.7%
EPS YoY
+254.9%
Gross Margin
+96.6%
Op Margin
-3432.2%
Net Debt
-$637.36M
Current Ratio
9.03
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data